Compare ARGX & WDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | WDC |
|---|---|---|
| Founded | 2008 | 1970 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1B | 41.3B |
| IPO Year | 2017 | N/A |
| Metric | ARGX | WDC |
|---|---|---|
| Price | $861.95 | $166.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 24 |
| Target Price | ★ $974.76 | $149.17 |
| AVG Volume (30 Days) | 343.8K | ★ 7.0M |
| Earning Date | 10-30-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 0.29% |
| EPS Growth | N/A | ★ 578.01 |
| EPS | ★ 23.27 | 6.90 |
| Revenue | $3,683,281,000.00 | ★ $10,126,000,000.00 |
| Revenue This Year | $91.22 | $24.25 |
| Revenue Next Year | $36.36 | $12.58 |
| P/E Ratio | $34.15 | ★ $25.31 |
| Revenue Growth | ★ 92.98 | 75.22 |
| 52 Week Low | $510.06 | $28.83 |
| 52 Week High | $934.62 | $188.77 |
| Indicator | ARGX | WDC |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 52.93 |
| Support Level | $827.52 | $170.02 |
| Resistance Level | $917.71 | $188.77 |
| Average True Range (ATR) | 17.62 | 10.00 |
| MACD | -9.56 | -0.39 |
| Stochastic Oscillator | 33.15 | 40.48 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.